Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
32.98
+0.19 (0.56%)
Nov 21, 2024, 1:54 PM EST - Market open
HRMY Revenue
Harmony Biosciences Holdings had revenue of $186.04M in the quarter ending September 30, 2024, with 16.08% growth. This brings the company's revenue in the last twelve months to $681.88M, up 25.83% year-over-year. In the year 2023, Harmony Biosciences Holdings had annual revenue of $582.02M with 32.93% growth.
Revenue (ttm)
$681.88M
Revenue Growth
+25.83%
P/S Ratio
2.75
Revenue / Employee
$2,771,866
Employees
246
Market Cap
1.88B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Patterson Companies | 6.53B |
National HealthCare | 1.22B |
Tandem Diabetes Care | 854.35M |
Azenta | 656.32M |
Supernus Pharmaceuticals | 651.97M |
NeoGenomics | 644.12M |
Beam Therapeutics | 349.64M |
MannKind | 267.20M |
HRMY News
- 5 hours ago - HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES - PRNewsWire
- 9 days ago - Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points - Seeking Alpha
- 21 days ago - Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders - PRNewsWire
- 22 days ago - Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders - PRNewsWire
- 23 days ago - Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024 - PRNewsWire
- 7 weeks ago - HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY - PRNewsWire
- 2 months ago - HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024 - PRNewsWire